Read by QxMD icon Read

Pet psma

Sirong Chen, Shing Kee Cheung, Ka-Nin Wong, Kwok Kee Wong, Chi-Lai Ho
A bedridden 90-year-old man with fever and elevated prostate-specific antigen (PSA) (49 ng/mL) was referred for differentiation between infection and tumor. F-FDG PET/CT was negative for infection, but Ga-PSMA PET/CT showed multiple lesions in prostate gland with infiltration to bladder wall and seminal vesicle, consistent with locally advanced prostate cancer. The lesion with the highest Ga-PSMA uptake was strongly avid for Ga-DOTATOC, suggesting neuroendocrine tumor differentiation. After hormonal therapy, PSA normalized, but chromogranin-A increased (from 251 to 398 ng/mL), inferring progression of neuroendocrine tumor differentiation...
October 18, 2016: Clinical Nuclear Medicine
Mico Chan, Geoffrey Paul Schembri, Edward Hsiao
Ga prostate-specific membrane antigen (PSMA) PET/CT is increasingly used to evaluate extent of disease in prostate carcinoma. Several other benign and malignant pathologies have also been reported to demonstrate PSMA avidity. We present a case of serous cystadenoma of the pancreas showing focal uptake on PSMA PET/CT.
October 18, 2016: Clinical Nuclear Medicine
Susanne Lütje, Sebastian Blex, Benedikt Gomez, Benedikt M Schaarschmidt, Lale Umutlu, Michael Forsting, Walter Jentzen, Andreas Bockisch, Thorsten D Poeppel, Axel Wetter
OBJECTIVE: The aim of this optimization study was to minimize the acquisition time of 68Ga-HBED-CC-PSMA positron emission tomography/magnetic resonance imaging (PET/MRI) in patients with local and metastatic prostate cancer (PCa) to obtain a sufficient image quality and quantification accuracy without any appreciable loss. METHODS: Twenty patients with PCa were administered intravenously with the 68Ga-HBED-CC-PSMA ligand (mean activity 99 MBq/patient, range 76-148 MBq) and subsequently underwent PET/MRI at, on average, 168 min (range 77-320 min) after injection...
2016: PloS One
Jeffrey J Tosoian, Michael A Gorin, Steven P Rowe, Darian Andreas, Zsolt Szabo, Kenneth J Pienta, Martin G Pomper, Tamara L Lotan, Ashley E Ross
No abstract text is available yet for this article.
September 19, 2016: Clinical Genitourinary Cancer
Thorsten Derlin, Desiree Weiberg, Jan M Sohns
Paget disease is a chronic disorder resulting in enlarged and misshapen bones, and is caused by disorganized bone remodeling. We present the case of an 85-year-old man with prostatic adenocarcinoma and known Paget disease of the right iliac bone who underwent Ga-prostate-specific membrane antigen ligand, C-acetate, and F-fluoride PET/CT for restaging of cancer. On all PET scans, increased tracer accumulation was observed in Paget disease of bone. Besides that Paget disease may mimic metastases on PET/CT using various radiotracers, including Ga-prostate-specific membrane antigen ligands and C-acetate, this case highlights the potential of multiparametric disease characterization on PET...
October 5, 2016: Clinical Nuclear Medicine
Arun Sasikumar, Ajith Joy, Raviteja Nanabala, Madhavan Unni, Padmanabhan Tk
We describe a case of metastatic clear cell renal cell carcinoma with intensely tracer concentrating lesions in left suprarenal region, mediastinal lymph nodes, lytic bone lesions, thyroid nodules, and mild abnormal tracer-avid lung nodules in Ga-prostate-specific membrane antigen (PSMA) PET/CT. On the other hand F-FDG PET/CT showed mild to no significant abnormal uptake in these lesions. Complimentary uptake pattern was observed in Ga-PSMA and F-FDG PET images in thyroid lesions and D5 vertebral lesion. This case highlights the possibilities of imaging clear cell renal cell carcinoma with Ga-PSMA and opens the possibility of treatment with Lu-PSMA...
October 5, 2016: Clinical Nuclear Medicine
Shankar Vamadevan, Ken Le, Chuong Bui, Robert Mansberg
A 68-year-old man with treated prostate cancer 3 years earlier and small cleaved B-cell follicular lymphoma diagnosed 1 year prior and monitored clinically with no active intervention ("watch and wait" approach) was referred for Ga-prostate-specific membrane antigen (PSMA) PET/CT with rising prostate-specific antigen level. PET/CT demonstrated diffuse PSMA uptake in the prostate (SUVmax 3.6) and multiple PSMA-avid nonenlarged lymph nodes. Moderate PSMA uptake (SUVmax 4.7) was also noted in an enlarged right inguinal lymph node (SUVmax 4...
October 5, 2016: Clinical Nuclear Medicine
Hemant Bhardwaj, Maximilian Stephens, Manoj Bhatt, Paul Anthony Thomas
We report a case of a benign liver hemangioma with intense prostate-specific membrane antigen (PSMA) uptake on Ga PET/CT. A 77-year-old man with prostate adenocarcinoma underwent routine staging with PSMA PET/CT. This revealed an intensely PSMA-avid liver lesion. The known prostate adenocarcinoma was localized and had mild uptake. Diagnostic CT and MRI were characteristic of a hemangioma without interval growth over a 3-month period. PSMA PET/CT is becoming increasingly popular for staging in prostate cancer, and the presence of PSMA uptake in extra-prostatic tumors is being increasingly documented...
October 5, 2016: Clinical Nuclear Medicine
Axel Bode, Kambiz Rahbar, Julia Konnert, Martin Bögemann, Lars Stegger
A 66-year-old man with castration-resistant prostate carcinoma and multiple symptomatic bone mestastases was considered for Ra-dichloride (Xofigo) therapy. Staging with Ga-PSMA-PET/CT revealed additional extensive tumor involvement of the spine without relevant uptake in bone scintigraphy. Based on this imaging result, the patient was rescheduled for a PSMA-targeted therapy. Additional Ga-PSMA-PET/CT may have a considerable benefit for patients considered for Xofigo.
October 5, 2016: Clinical Nuclear Medicine
Robert M Hermann, Manoutschehr Djannatian, Norbert Czech, Mirko Nitsche
We report on a 72-year-old male patient who developed sarcoidosis of the mediastinal lymph nodes, the liver, and the prostate 11 years ago. Seven years later, he underwent transurethral resection of the prostate by laser due to hematuria. Pathology of the resected chips showed a 'granulomatous prostatitis with epitheloid cells'. Malignancy was histologically excluded at that time. Four years later, he was diagnosed with an undifferentiated prostate carcinoma, with a Gleason score of 5 + 4 = 9. After initiation of antihormonal therapy, he underwent radical prostatectomy and pelvic lymphadenectomy, which revealed a pT3b pN1 carcinoma with infiltrated resection margins...
May 2016: Case Reports in Oncology
Bernhard Grubmüller, Richard P Baum, Enza Capasso, Aviral Singh, Yasaman Ahmadi, Peter Knoll, Andreas Floth, Sergio Righi, Shahin Zandieh, Carlo Meleddu, Shahrokh F Shariat, Hans Christoph Klingler, Siroos Mirzaei
AIM: The prostate-specific membrane antigen (PSMA) is a cell surface protein, which is overexpressed in nearly all cases of prostate cancer (PCa). PET imaging with (68)Ga-PSMA-HBED-CC has recently found widespread application in the diagnosis of recurrent PCa. In this study, the diagnostic potential of (64)Cu-labeled PSMA ligand (PSMA-617) PET in patients with PCa has been investigated. MATERIALS AND METHODS: The study was conducted simultaneously at two nuclear medicine centers, Austria (Vienna, Center 1) and Germany (Bad Berka, Center 2)...
October 7, 2016: Cancer Biotherapy & Radiopharmaceuticals
Arun Sasikumar, Ajith Joy, M R A Pillai, Vikraman Raman, Arun Vasudevan, Jayaprakash Madhavan
No abstract text is available yet for this article.
October 4, 2016: European Journal of Nuclear Medicine and Molecular Imaging
Harshad R Kulkarni, Aviral Singh, Christiane Schuchardt, Karin Niepsch, Manal Sayeg, Yevgeniy Leshch, Hans-Juergen Wester, Richard P Baum
A potential milestone in personalized nuclear medicine is theranostics of metastatic castration-resistant prostate cancer (mCRPC) based on molecular imaging using PET/CT with (68)Ga-labeled prostate-specific membrane antigen (PSMA) ligands and molecular radiotherapy using PSMA-targeted radioligand therapy (PRLT) with (177)Lu-PSMA ligands. (68)Ga-PSMA PET/CT enables accurate detection of mCRPC lesions with high diagnostic sensitivity and specificity and provides quantitative and reproducible data that can be used to select patients for PRLT and therapeutic monitoring...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Steven P Rowe, Alexander Drzezga, Bernd Neumaier, Markus Dietlein, Michael A Gorin, Michael R Zalutsky, Martin G Pomper
Radiohalogenated agents are often the first line of pursuit in the development of new radiopharmaceuticals-whether antibodies, peptides, or small molecules-because of their ease of synthesis, lack of substantial steric perturbation of the original affinity agent (in some cases, providing enhanced affinity), and capacity to be transformed into therapeutics (in some cases, with a mere switch of an isotope). They often provide proof of a principle before optimization for pharmacokinetics or generation of radiometallated agents, when the latter are necessary...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Ali Afshar-Oromieh, John W Babich, Clemens Kratochwil, Frederik L Giesel, Michael Eisenhut, Klaus Kopka, Uwe Haberkorn
The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. After many years of outstanding preclinical research, the first significant step forward in clinical use was achieved in 2008 with the first human experience with the small-molecule PSMA inhibitors (123)I-MIP-1972 and (123)I-MIP-1095. A clinical breakthrough followed in 2011 with (68)Ga-PSMA-11 for PET imaging and (131)I-MIP-1095 for endoradiotherapy of metastatic prostate cancer...
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Wolfgang P Fendler, Svenja Reinhardt, Harun Ilhan, Andreas Delker, Guido Böning, Franz J Gildehaus, Christian Stief, Peter Bartenstein, Christian Gratzke, Sebastian Lehner, Axel Rominger
Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen (PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC).Fifteen patients each received two cycles of 3.7 GBq (n = 5) or 6.0 GBq (n = 10) 177Lu-PSMA-617 at an eight to ten weeks interval. For safety monitoring, each treatment was followed by dosimetry with serial quantitative SPECT as well as inpatient and outpatient recording of adverse events...
September 24, 2016: Oncotarget
Martin Barrio, Wolfgang P Fendler, Johannes Czernin, Ken Herrmann
Prostate specific membrane antigen (PSMA) has become an attractive diagnostic and therapeutic target for small molecule ligands. Radionuclide-chelating ligands can be labeled with either (68)Ga for positron-emission-tomography (PET) or (177)Lu for radionuclide therapy. Areas covered: In this literature review we evaluate the diagnostic value of (68)Ga PSMA PET/CT and the therapeutic potential of (177)Lu PSMA radioligand therapy (RLT) in patients with prostate cancer. (68)Ga PSMA PET/CT is more accurate than CT for nodal staging and superior to conventional imaging in patients with biochemical recurrence, translating into major changes in clinical management...
October 14, 2016: Expert Review of Molecular Diagnostics
C Zamboglou, F Schiller, T Fechter, V Drendel, M Mix, P T Meyer, A Grosu
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
T Elri, M Aras, Y S Salihoglu, R U Erdemir, M Cabuk
No abstract text is available yet for this article.
September 22, 2016: Revista Española de Medicina Nuclear e Imagen Molecular
L Michaud, K A Touijer
INTRODUCTION: Prostate cancer is the most frequent cancer in men in France and it is a public health issue. This cancer is heterogenous. There is a clinical need of an accurate non-invasive imaging method to improve diagnosis, guide the choice of therapy and evaluate its efficacy. We undertook to critically review the different molecular imaging probes, currently used or in clinical trial. METHOD: A systematic review of the literature was performed in Pubmed/Medline database by searching for articles in French or English published on PET tracer in prostate cancer in clinical application...
September 20, 2016: Progrès en Urologie
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"